- Home
- FLYE vs KZIA Comparison
FLYE vs KZIA Comparison
Compare FLYE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | KZIA |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 74.4M |
| IPO Year | 2024 | 1999 |
Fundamental Metrics
Financial Performance| Metric | FLYE | KZIA |
|---|---|---|
| Price | $7.37 | $7.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 256.4K | ★ 257.7K |
| Earning Date | 02-18-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,966,391.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $2.86 |
| 52 Week High | $161.80 | $17.40 |
Technical Indicators
Market Signals| Indicator | FLYE | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 45.63 |
| Support Level | $6.75 | $6.07 |
| Resistance Level | $8.40 | $7.08 |
| Average True Range (ATR) | 0.94 | 0.83 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 56.20 | 82.28 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.